

2022

YEAR IN REVIEW

A Powerful Story Continues

13.5%

Savings for clients in 2022¹

10.6%

Present Value (PV) of savings, from implementation to 2022¹

58% Growth over 2021 ▶

2,378%

Return on investment (ROI) for clients in 2022

2,263%

ROI for clients from implementation to 2022

-5.2%

Average inflation rate among Reformulary clients in 2022², compared to -1.1% average inflation rate among private plan³

59+7

Evidence-based review of 59 new drugs and/or new indications, as well as 7 drug class reviews

Benefits, All Around


Reformulary clients continue to reinvest savings and/or ROI back into enhancing plan member benefits, such as: increased reimbursement for drugs; enhanced mental health benefit; new vision care benefit.

Quick on the Uptake

BIOSIMS™, POWERED BY REFORMULARY

Successful transition from Biologics to biosimilars, from April to October 2022. 63% uptake within 2 months post-transition.

+63%



Reality Check

Psoriasis Study

New- versus old-generation biologics: Collaborated with CADTH on major study looking at patient outcomes in plaque psoriasis treatments.




Migraine Study

Traditional versus newer migraine treatments: Published with partner study of real-world adherence and switching patterns among migraine medications.

ADHD, or attention deficit hyperactivity disorder

Pre-versus post-pandemic ADHD drug utilization. Released data showing 36% more claimants taking ADHD drugs as of Q3 2022 than pre-pandemic; as well as dramatic shift in claimants of ADHD drugs, from under 18s to 25- to 44-year-olds. Within 25- to 44-year-olds, 120% increase in females claiming ADHD drugs.

Diversity, Equity, Inclusion.



10-member team represents
6 nationalities
12 languages

OUR PURPOSE

To make medicine make sense – and, ultimately, make more drugs more affordable for more Canadians.

Footnotes

1. Based on Per Member Per Year (PMPY) and negotiated discounts, for top clients with full 12 months of pre-Reformulary data or documented year 1 savings.
2. Based on Per Member Per Year, across all DINs on the Reformulary, for individual clients (association plans excluded).
3. Private plans comprising \$1.65B drug spend in 2022.

